Leveraging Evolving Data to Inform Treatment in HR-Positive, HER2-Negative Advanced Breast Cancer
  • CME
  • MOC

In this CME/MOC-certified, on-demand Webcast of a CCO symposium at SABCS 2019, a panel of experts review and discuss evolving strategies for treating HR-positive, HER2-negative advanced breast cancer.
Joyce O'Shaughnessy, MD
Program Director
Hope S. Rugo, MD
Eric P. Winer, MD
Physicians: maximum of 1.75 AMA PRA Category 1 Credits
US Physicians: maximum of 1.75 Medical Knowledge MOC point(s)
Released: January 21, 2020 Expiration: January 20, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Plan optimal treatment strategies for patients with HR+/HER2- advanced breast cancer based on available data, updated clinical guidelines, and expert recommendations
  • Appropriately integrate PI3K/Akt/mTOR and CDK4/6-targeted therapies into clinical practice for optimal personalized medicine for pre-, peri-, and postmenopausal patients with HR+/HER2- breast cancer
  • Manage adverse events associated with multidrug treatment regimens and recognize potential drug–drug interactions to improve patient outcomes
  • Discuss emerging research, the mechanisms of action, and the role of novel therapies and combinations in clinical investigation for patients with HR+/HER2- breast cancer

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Joyce O'Shaughnessy, MD

Celebrating Women Chair in Breast Cancer Research
Breast Cancer Research Program
Baylor University Medical Center
Texas Oncology
US Oncology Network
Dallas, Texas

Joyce O’Shaughnessy, MD, has disclosed that she has received consulting fees from AbbVie, Agendia, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron, Ipsen, Jounce, Lilly, Merck, Myriad, Novartis, Odonate, Pfizer, Puma, Roche, Seattle Genetics, and Syndax.


Hope S. Rugo, MD

Professor of Medicine
Director, Breast Cancer and Clinical Trials Education
Division of Hematology/Oncology
Department of Medicine
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Hope S. Rugo, MD, has disclosed that she has received funds for research support from Amgen, Daiichi, Eisai, Genentech, Immunomedics, Lilly, MacroGenics, Merck, Novartis, OBI, Odonate, Pfizer, and Seattle Genetics and support for travel from Amgen, AstraZeneca, Daiichi, MacroGenics, Merck, Mylan, Pfizer, and Puma.
Eric P. Winer, MD

Director, Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Eric P. Winer, MD, has disclosed that he has received consulting fees from Carrick Therapeutics, Genentech/Roche, Genomic Health, GlaxoSmithKline, Jounce, Leap, Lilly, Merck, and Seattle Genetics and funds for research support from Genentech/Roche and Merck.


Rachael M. Andrie, PhD

Scientific Director

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Taryn O'Loughlin Gross, PhD

Editorial Contributor

Taryn O’Loughlin Gross, PhD, has disclosed that she has received fees for non-CME/CE services from Harmony Biosciences, Saluda Medical, and Shionogi.
Gordon Kelley

Senior Clinical Editor

Gordon Kelley has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason J. Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with HR-positive/HER2-negative breast cancer.


The goal of this activity is to improve participants’ knowledge, confidence, and competence at selecting individualized treatment for patients with hormone receptor–positive breast cancer.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board on Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 21, 2020, through January 20, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Joyce O’Shaughnessy, MD, provides insights on key studies in HR-positive/HER2-negative breast cancer from 2019 SABCS for Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Released: January 31, 2020

Sara Tolaney, MD, MPH, provides insights on key studies on the treatment of HER2-negative and triple-negative breast cancer from 2019 SABCS for Clinical Care Options (CCO)

Sara Tolaney, MD, MPH Released: January 27, 2020

CCO faculty Dr. Heather McArthur provides insights on trastuzumab deruxtecan and tucatinib for patients with HER2+ MBC who have progressed on standard-of-care HER2-targeted therapies

Heather McArthur, MD, MPH Released: January 21, 2020

CCO faculty Sara Hurvitz, MD, FACP, provides her thoughts on key studies in HER2+ breast cancer presented at the 2019 Breast Cancer meeting in San Antonio

Sara Hurvitz, MD, FACP Released: January 13, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Immunomedics, Inc.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?